Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305780 · ClinicalTrials.gov registry record · Phase 2
RECOVER-AUTONOMIC Platform Protocol
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 381
- Enrollment target
NCT06305780: Completed Phase 2 study, sponsored by Kanecia Obie Zimmerman.
NCT06305780 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 381 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (186% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305780, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 381 participants
- Enrollment target
Study Summary
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.
Interventions
- DRUG IVIG + Coordinated Care
- DRUG IVIG Placebo + Coordinated Care
- DRUG Ivabradine + Coordinated Care
- DRUG Ivabradine Placebo + Coordinated Care
- DRUG IVIG + Usual Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
What the finished NCT06305780 record still lists
NCT06305780 is an interventional study that assigns participants to a tested intervention. The registered 381 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (186% higher).
The record links to 0 conditions, and to 5 interventions - of which IVIG + Coordinated Care is the first listed.
NCT06305780 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06305780 about?
NCT06305780 is a clinical study titled "RECOVER-AUTONOMIC Platform Protocol". This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-ar...
What is the current status of trial NCT06305780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 381 participants. The study started on 2024-03-11. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT06305780?
The interventions under investigation include: IVIG + Coordinated Care (DRUG), IVIG Placebo + Coordinated Care (DRUG), Ivabradine + Coordinated Care (DRUG), Ivabradine Placebo + Coordinated Care (DRUG), IVIG + Usual Care (DRUG).
Who is sponsoring clinical trial NCT06305780?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06305780's enrollment target sits among peer trials
381 111th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI